Kristin Kaasen Jørgensen
Position: PhD, Associated post.doc, MD
Phone: +47 23 07 06 46
Email:
 

Publications 2017

Jørgensen KK, Lundin KE, Olsen IC, Kvien TK, Jahnsen J (2017)
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Lancet, 390 (10111), 2436
PubMed 29208304

Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, NOR-SWITCH study group (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Lancet, 389 (10086), 2304-2316
PubMed 28502609

Publications 2016

Henriksen EK, Jørgensen KK, Kaveh F, Holm K, Hamm D, Olweus J, Melum E, Chung BK, Eide TJ, Lundin KE, Boberg KM, Karlsen TH, Hirschfield GM, Liaskou E (2016)
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
J Hepatol, 66 (1), 116-122
PubMed 27647428

Jørgensen SF, Reims HM, Frydenlund D, Holm K, Paulsen V, Michelsen AE, Jørgensen KK, Osnes LT, Bratlie J, Eide TJ, Dahl CP, Holter E, Tronstad RR, Hanevik K, Brattbakk HR, Kaveh F, Fiskerstrand T, Kran AB, Ueland T, Karlsen TH, Aukrust P, Lundin KE, Fevang B (2016)
A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency
Am J Gastroenterol, 111 (10), 1467-1475
PubMed 27527747

Zenouzi R, Weismüller TJ, Jørgensen KK, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen TH, Boberg KM, Manns MP, Lohse AW, Schramm C (2016)
No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 14 (12), 1806-1812
PubMed 27521513

Publications 2013

Block M, Jørgensen KK, Oresland T, Lindholm E, Grzyb K, Cvancarova M, Vatn MH, Boberg KM, Börjesson L (2013)
Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis - what next?
J Crohns Colitis, 8 (5), 421-30
PubMed 24239402

Jørgensen KK, Lindström L, Cvancarova M, Karlsen TH, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM (2013)
Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease
Clin Gastroenterol Hepatol, 11 (5), 517-23
PubMed 23333218

Publications 2012

Jørgensen KK, Lindström L, Cvancarova M, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM (2012)
Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study
Scand J Gastroenterol, 47 (8-9), 1021-9
PubMed 22577871

Publications 2011

Jørgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, Vatn MH, Boberg KM (2011)
Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients
Inflamm Bowel Dis, 18 (3), 536-45
PubMed 21456044

Publications 2010

Ricanek P, Lothe SM, Szpinda I, Jorde AT, Brackmann S, Perminow G, Jørgensen KK, Rydning A, Vatn MH, Tønjum T, IBSEN II study group (2010)
Paucity of mycobacteria in mucosal bowel biopsies from adults and children with early inflammatory bowel disease
J Crohns Colitis, 4 (5), 561-6
PubMed 21122560